Cloning of Plasmodium falciparum protein disulfide isomerase homologue by affinity purification using the antiplasmodial inhibitor 1,4-bis{3-[N-(cyclohexyl methyl)amino]propyl}piperazine 11Nucleotide sequence data reported in this paper are available in the EMBL, GenBank™ and DDJB databases under accession number AJ250363.  by Florenta, Isabelle et al.
Cloning of Plasmodium falciparum protein disul¢de isomerase homologue
by a⁄nity puri¢cation using the antiplasmodial inhibitor
1,4-bis{3-[N-(cyclohexyl methyl)amino]propyl}piperazine 1
Isabelle Florentaa;*, Elisabeth Mouraya, Fouad Dali Alia, Herve¤ Drobecqb, Sophie Giraultb,
Joseph Schre¤vela, Christian Sergheraertb, Philippe Grelliera
aLaboratoire de Biologie et Evolution des Parasites, FR CNRS 63, Muse¤um National d’Histoire Naturelle 61, rue Bu¡on, 75005 Paris, France
bUMR 8525 CNRS, Universite¤ de Lille II, Institut de Biologie et Institut Pasteur de Lille 1, rue du Professeur Calmette, P.O. Box 447, 59021 Lille,
France
Received 4 May 2000; revised 17 October 2000; accepted 18 October 2000
First published online 27 October 2000
Edited by Veli-Pekka Lehto
Abstract A series of 10 1,4-bis(3-aminopropyl)piperazine
compounds was found to display antiplasmodial activity with
50% growth inhibition between 30 and 250 nM, on three
Plasmodium falciparum strains differently sensitive to chlo-
roquine. By affinity chromatography using one of these
compounds, a 52-kDa protein was isolated from P. falciparum,
microsequenced and cloned. It corresponded to a single copy gene
encoding a 453 amino acid protein displaying the typical features
of protein disulfide isomerases, a thiol metabolizing enzyme
belonging to the thiol : disulfide oxidoreductase superfamily,
which was not previously described in malarial species. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Malaria, caused by protozoan parasites of the genus Plas-
modium, is one of the most dangerous tropical infectious dis-
eases a¡ecting human populations [1]. The Plasmodium falci-
parum species is the greatest cause of human malarial
morbidity and mortality. The resistance of the parasite to
drugs and the resistance of mosquitoes to insecticides have
resulted in a resurgence of malaria in many parts of the world
and in a pressing need for vaccines and alternative chemo-
therapeutic drugs.
The analysis of thiol metabolism in parasitic protozoa has
resulted in an exploitation of their original pathways and the
particularities displayed by some parasitic enzymes, towards
the development of alternative chemotherapeutic strategies [2].
For example, Trypanosomes and Leishmania use trypano-
thione reductase instead of glutathione reductase and the for-
mer, being absent from mammalian cells, has emerged as a
promising drug target [3]. In Plasmodium, glutathione plays
an important role in parasite development [4]. P. falciparum
possesses host-independent mechanisms of de novo synthesis
or regeneration of glutathione [5], and P. falciparum genes
encoding glutathione reductase [6,7], a non-selenium gluta-
thione peroxidase homologue [8], and Q-glutamylcysteine syn-
thetase [9] have been isolated. The corresponding enzymes are
now considered as putative antiplasmodial targets, which re-
main however to be validated [10,11].
To further investigate thiol metabolism in P. falciparum, we
set up the testing of series of inhibitors known to interact with
thiol metabolism in other parasite protozoa or in eukaryotic
cells. A series of 1,4-bis(3-aminopropyl)piperazine inhibitors
displaying a high in vitro trypanocidal activity on Trypanoso-
ma cruzi while being inactive against the puri¢ed trypano-
thione reductase was selected [12], this approach was
prompted because a⁄nity chromatography using one of these
inhibitors, led to the isolation of the T. cruzi Tc52 enzyme [13]
which turned out to be an new member of the thiol : disul¢de
oxidoreductase family [14,15], and to be essential for the para-
site growth [16].
In the present study, we show that this series of 1,4-bis(3-
aminopropyl)piperazine compounds, displays a high in vitro
antiplasmodial activity against P. falciparum. Searching for
their plasmodial targets by a⁄nity chromatography using
one of these compounds as a ligand, the homologue of protein
disul¢de isomerase (PDI, EC 5.3.4.1) was isolated. This en-
zyme, not previously described in malarial species, belongs to
the superfamily of thiol : disul¢de oxidoreductases having se-
quence and structural similarity to thioredoxin [17]. Its iden-
ti¢cation and molecular characterization are presented there-
after.
2. Materials and methods
2.1. Chemicals
1,4-bis(3-{N-[4-(benzyloxy)benzyl]amino}propyl)piperazine (com-
pound 1), 1,4-bis(3-{N-[4-(phenyl)benzyl]amino}propyl)piperazine
(compound 2), 1,4-bis{3-[N-(4-chlorobenzyl) amino]propyl}piperazine
(compound 3), 1,4-bis{3-[N-(napht-2-ylmethyl)amino]propyl} pipera-
zine (compound 4), 1,4-bis(3-{N-[3,4-(dibenzyloxy) benzyl]amino}-
propyl)piperazine (compound 5), 1,4-bis{3-[N-(£uoren-2-ylmethyl)-
amino]propyl}piperazine (compound 6), 1,4-bis(3-{N-[4-(nitrobenzyl)-
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amino]propyl}piperazine (compound 7), 1,4-bis{3-[N-(cyclohexyl-
methyl)amino]propyl}piperazine (compound 8), 1,4-bis{3-[N-(anthr-
9-ylmethyl) amino]propyl}piperazine (compound 9), 1,4-bis{3-[N-
(adamantylmethyl)amino]propyl} piperazine (compound 10) were
syn- thesized according to [12], 1,4-bis[3-(N-cyclohexylmethyl-NP-{4-
[N-(2,6-diaminohexan-1-oxo)aminomethyl]cyclohexylmethyl}amino)-
propyl]piperazine (compound 8b), was synthesized according to [13].
Stock solutions of inhibitors were prepared in DMSO at 10 mM
and stored at 320‡C. Chloroquine (CQ) was purchased from Sigma
Aldrich (France).
2.2. P. falciparum in vitro culture, metabolic labeling and drug
susceptibility assays
P. falciparum strains were maintained in vitro, on human red blood
cells (RBC) in RPMI 1640 medium supplemented with 7.5% heat-
inactivated human serum [18]. Metabolic labeling was performed in
culture medium without methionine and cysteine by adding 50 WCi.
ml31 of [35S]methionine/[35S]cysteine mix (Amersham Pharmacia Bio-
tech, France) for 12 h, just prior to parasite harvest. Drug assays were
performed by measuring [3H]hypoxanthine incorporation in 96-well
plates [19]. Parasite growth inhibition was determined by comparison
of the radioactivity incorporated in treated cultures with that of con-
trol cultures maintained without drug. The concentrations causing
50% growth inhibition (IC50) were obtained from the drug concen-
tration^response curves.
2.3. A⁄nity chromatography, protein microsequencing and gel ¢ltration
Infected RBC were washed three times (600Ug, 5 min) in cold
phosphate-bu¡ered saline (PBS, 140 mM NaCl, 2.5 mM KCl, 1 mM
KH2PO4, 8 mM Na2HPO4, pH 7.4) and lysed in 10 volumes of PBS
containing 0.2% saponin (Sigma Aldrich) and a protease inhibitor
cocktail (Complete1 EDTA-free, Boehringer Mannheim), during
5 min on ice. The released parasites were washed four times in cold
PBS (10 000Ug, 10 min) and were lysed by three cycles of freezing^
thawing in 10 mM HEPES (pH 7.5) in presence of the protease in-
hibitor cocktail. Soluble extracts were obtained by a 100 000Ug cen-
trifugation (1 h, 4‡C).
Compound 8b was anchored onto activated CH Sepharose CL4B
gel (N-hydroxysuccinimide ester) [13]. Parasite extracts were previ-
ously cleared of molecules binding non-speci¢cally to the matrix by
being loaded three times on a 3-ml Sepharose CL4B column, equili-
brated with bu¡er A (20 mM HEPES, 150 mM KCl, pH 7.5). The
cleared extract was then loaded three times on the 3-ml a⁄nity col-
umn, also previously equilibrated with bu¡er A, and was washed with
100 ml of bu¡er A then 100 ml of bu¡er B (20 mM HEPES, 500 mM
KCl, pH 7.5). Competitive elution was performed with 100 ml of
bu¡er B containing 5 mM compound 8b [13]. A ¢nal wash was per-
formed with 100 ml of bu¡er C (20 mM HEPES, 2 M KCl, pH 7.5).
Flow rate was 1 ml min31 and 5 ml fractions were collected during all
the procedure. Pooled fractions, concentrated by ultra¢ltration on
Amicon centriprep 10 (Millipore Corporation, Bedford, MA, USA),
were analyzed by sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) [20]. After Coomassie blue staining, the band
of interest was excised from the gel and subjected to in-gel proteolysis
[21]. Peptides were puri¢ed by reverse phase HPLC on a Beckman
ultrasphere ODS column 2 mm/200 mm, eluted with a linear gradient
of acetonitrile in TFA 0.1%. Isolated peptides were sequenced in a
Perkin-Elmer Procise 492. Gel ¢ltration was performed on a Superose
12 column (Amersham Pharmacia Biotech) in bu¡er A at a £ow rate
of 0.4 ml min31 and 0.6 ml fractions were collected. Each fraction was
analyzed by SDS^PAGE. Calibration of the Superose 12 column was
done according to the manufacturer’s recommendations.
2.4. Genomic DNA and RNA preparations, Southern blotting and
library screening
Genomic DNA was prepared from free parasites by using standard
procedures [22] and total RNA was extracted from free parasites by
using the RNAgents0 total RNA isolation system (Promega, France).
Genomic DNA was digested with restriction enzymes (Promega), frac-
tionated by agarose gel electrophoresis and transferred to nylon mem-
branes prior to being hybridized to [K-32P]dATP radiolabeled nucle-
otide probes as previously described [23]. Genomic DNA library,
containing EcoRI genomic fragments from the FcB1 strain inserted
into Vgt11 was plated and probed with [K-32P]dATP radiolabeled
DNA fragments as previously described [23]. Isolated plaques were
grown for isolation of recombinant bacteriophages by using standard
procedures [22].
2.5. Reverse transcription-polymerase chain reaction (RT-PCR) and
oligonucleotides
Ampli¢cations on genomic DNA were done by combining 200 ng
of genomic DNA with 200 nM degenerated or non-degenerated oli-
gonucleotides (Genaxis, France) in a standard 50-Wl PCR mixture
using Taq-Polymerase (Finzyme, Ozyme, France), and performing
30 cycles (94‡C for 30 s, 42^68‡C for 120 s, 74‡C for 3^6 min) in a
Perkin-Elmer 9600 thermal cycler. Inserts from recombinant bacter-
iophages were ampli¢ed by using forward and reverse Vgt11 insert
primers (Ozyme). RT-PCR was performed by combining 1 Wg of total
RNA treated with RQ1 DNase (Promega), random hexamers and
avian myeloblastosis virus reverse transcriptase as recommended
(Promega), in a ¢nal volume of 50 Wl, of which 10 Wl were then
directly added to a 40-Wl standard PCR reaction. The sequences of
oligonucleotides P2S and P5AS are (5P-CCWGAATATGCWGAA-
CATGC-3P) and (5P-WCCWGGAAATTCWGTTTAWCC-3P) respec-
tively, where W = A+T, and were used at an annealing temperature of
42‡C. The sequences of oligonucleotides N5S and N5AS are (5P-
AAAAAGAAAAAATGAACAGAAAG-3P) and (5P-TTTTTGATT-
TTTTTGTTTTTCATG-3P) respectively. All ampli¢ed fragments
were excised from preparative agarose gel by using the Quiaex proce-
dure (Quiagen, Coger, France) and were either directly sequenced or
subcloned into pCR-Script1 (Stratagene, Ozyme).
2.6. DNA sequencing and sequence analysis
Dideoxy nucleotide sequence data were obtained by the dideoxy
chain termination method of Sanger [24] using the Sequenase version
2.0 kit (Amersham Pharmacia Biotech). Both strands of the genomic
locus and of the cDNA were sequenced at least two times. Sequence
analyses were performed by using the Bisance software (http://
www.infobiogen.fr) [25]. BLAST and PSI-BLAST searches [26] were
performed through the NCBI website (http://www.ncbi.org) against
non-redundant databases and against the International Malaria Ge-
nome Sequencing Consortium for the P. falciparum genome project
database (http://www.ncbi.nlm.nih.gov/Malaria/). Multiple sequence
alignments were performed with Clustal W [27] and further re¢ned
manually.
3. Results and discussion
3.1. In vitro antiplasmodial activity of 1,4-bis(3-aminopropyl)
piperazine derivatives
Compounds selected for their trypanocidal activity against
T. cruzi [12] that were tested upon P. falciparum are presented
in Table 1. They were symmetrical amine derivatives from the
1,4-bis(3-aminopropyl)piperazine, prepared by condensation
of the piperazine with a variety of aldehydes into imines which
Fig. 1. SDS^PAGE analysis of parasite proteins puri¢ed on com-
pound 8 a⁄nity column. Molecular weight markers (lane 1); pooled
fractions eluted by 5 mM of compound 8b (lane 2); pooled frac-
tions eluted by the 2 M KCl ¢nal washing step (lane 3). The gel
was silver-stained by standard procedures.
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were then transformed, by reductive amination. All the com-
pounds showed high in vitro antiplasmodial activity on three
di¡erent strains of P. falciparum, with IC50 values in the low
nanomolar range (V30^250 nM) (Table 1). These concentra-
tions are much lower than those reported for their cytotoxicity
on the human MRC 5 cell lines: absence of toxicity at 3 WM
[12]. Except for compounds 1, 3 and 9, the CQ-sensitive strain
appeared generally slightly more sensitive to the 1,4-bis(3-ami-
nopropyl) piperazine derivatives than the CQ-resistant strains.
To isolate parasite proteins interacting with these antiplasmo-
dial derivatives, 1,4-bis{3-[N-(cyclohexylmethyl)amino]prop-
yl} piperazine (compound 8) was selected for a⁄nity chroma-
tography, instead of the more active compounds 3 and 9
because of its similar antiplasmodial activity upon the three
strains and its absence of aromatic moieties that could lead to
an unsuccessful a⁄nity puri¢cation due to hydrophobic inter-
actions. Compound 8 was transformed into its analogue 8b,
presenting a lysine end to allow ¢xation to the Sepharose
polymer.
3.2. A⁄nity puri¢cation and microsequencing of a 52-kDa
parasite protein
Parasite extracts prepared from the FcB1 strain of P. falci-
parum were loaded on the compound 8b Sepharose gel. SDS^
PAGE analysis of the fractions allowed the clear identi¢cation
of a major 52-kDa (Pf52) and two minor 75 and 43-kDa
proteins, speci¢cally eluted in presence of 5 mM of compound
8b (Fig. 1, lane 2) and not by the ¢nal 2-M KCl wash (Fig. 1,
lane 3). These three proteins appeared to correspond to para-
site proteins, since they were all metabolically 35S-labeled
(data not shown). To test whether they could have eluted
from the a⁄nity column as complex(es), a gel ¢ltration of
the a⁄nity puri¢ed fraction (as on Fig. 1, lane 2) was per-
formed. SDS^PAGE analysis of the gel ¢ltration fractions
showed that each protein eluted in di¡erent fractions, with
retention times (as compared to a calibration curve) corre-
sponded to molecular weight of their respective monomeric
forms, indicating that they had not interacted on the a⁄nity
column as complexes (data not shown). Six peptide sequences
could be determined for Pf52: P1 (GFVDFLNK), P2
(THFVLLNIPEYAEHAK), P3 (XGDLFNQFVTDIH, where
X stands for an undetermined amino acid), P4 (ESLLNH-
NAIINFFK), P5 (ASLGLTEFPGLAFQSNEGRY) and P6
(LVSIDATSENAL), while no data were obtained for the
75- and 43-kDa proteins due to their insu⁄cient amounts.
3.3. Cloning and sequencing of the P. falciparum gene for Pf52
Since none of the six peptide sequences derived from Pf52
matched any molecule in any database that was searched,
degenerate oligonucleotides (P2S and P5AS) were synthesized
based on the peptide sequences P2 and P5, taking into ac-
count the biased codon usage typical of P. falciparum genes
[28]. A 609-bp fragment was ampli¢ed from the genomic
DNA of the FcB1 strain (nucleotide positions 449^1058 on
Fig. 2), which encoded a protein displaying similarities to PDI
from various species and similarities to three ‘preliminary se-
quence data’ in the P. falciparum genome project databases.
These latter were exploited to amplify most of the correspond-
ing gene from the genomic DNA of the FcB1 strain, while the
remaining 5P end of the gene was isolated from the genomic
library previously described [23]. The sequencing of the com-
plete cDNA, which was ampli¢ed by RT-PCR by using oli-
gonucleotides N5S and N5AS, con¢rmed the occurrence of a
155-bp intron (Fig. 2). The presented data correspond to the
FcB1 strain and it was checked by Southern blotting hybrid-
ization using the 609-bp fragment as a probe, that the locus
appeared to be in single copy in this P. falciparum genome
(data not shown).
3.4. Nucleotide and amino acid sequence analysis: evidence for
a P. falciparum gene encoding a typical PDI homologue
The A+T richness of the non-coding regions (91% upstream
of the ATG, 87% for the intron, and 89% downstream of the
stop codon) and of the coding regions (70% for the ¢rst exon,
68% for the second exon) were typical of P. falciparum genes
[29]. Analysis of the 483-amino acid sequence deduced from
the cDNA allowed to identify the six peptide sequences de-
rived from Pf52 and uncovered three additional features (Fig.
2). First, a putative signal peptide, with a most likely cleavage
site after the serine in position 24 was predicted by using the
method of Nielsen et al. [30]. Interestingly, the P3 sequence
would thus correspond exactly to the N-terminus of the ma-
ture enzyme, the theoretical molecular weight of which has
been calculated to be V52-kDa (459 residues). Second, a
putative ‘KDEL’ endoplasmic reticulum (ER) retention sig-
nal, was predicted with a score of 100% at the C-terminal
end of the sequence [31]. Third, two perfectly conserved thi-
oredoxin family active sites, the pattern of which is [LIVMF]-
[LIVMSTA]-x-[LIVMFYC]-[FYWSTHE]-x(2)-[FYWGTN]-C-
[GATPLVE]-[PHYWSTA]-C-x(6)-[LIVMFYWT], were found
in the sequence, and both corresponded to the WCGHCK
motif, which appears to be most favorable for PDIs [32].
Table 1
In vitro antiplasmodial activity of the 1,4-bis(3-aminopropyl) pipera-
zine derivatives
Chemical structure of the compounds and IC50 values measured on
the CQ-sensitive strain F32/Tanzania and the CQ-resistant strains
FcB1/Columbia and K1/Thailand. The IC50 (nM) values correspond
to the mean þ standard deviation from several independent experi-
ments (a: n = 4; b: n = 5).
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PDIs are V55-kDa multifunctional proteins, fairly abun-
dant in the ER of eukaryotic cells, known to be involved in
the formation, breakage and rearrangements, of disul¢de
bonds during the folding of secreted proteins [32]. Although
PDIs are typically found as dimers, monomers have been
reported. PDIs have also been found as part of protein com-
plexes where they could have a structural role in stabilizing
the folded state of the associated proteins [17]. Noticeably,
PDI has been proposed to act either as a chaperone or an
anti-chaperone, depending on its concentration [17]. Disrup-
tion of the PDI gene turned out to be lethal in Saccharomyces
cerevisiae [33].
PDIs are typically composed of ¢ve domains denoted a-b-
bP-aP-c [17]. Both a and aP domains (V110 residues each),
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Fig. 3. Multiple sequence alignment of P. falciparum PDI homologue and eukaryotic PDIs. The sequences of the mature form of Gallus gallus
PDI [42] and of the precursor forms of Homo sapiens [38], Medicago sativa [39], Humicola insolens [41], Saccharomyces cerevisiae [33], Crypto-
sporidium parvum [40] and P. falciparum PDIs and homologues have been aligned by using Clustal W. Identical residues (*), conserved substitu-
tions (:) and semi-conserved substitutions (.) between the seven sequences are indicated below the sequences. The two thioredoxin family active
sites (WCGHCK) as well as the putative ER retention signal (‘KDEL’) are boxed. The ¢ve PDI domains a-b-bP-aP-c [17] are indicated by ar-
rows above the sequences.
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which are similar to each other and well conserved between
species, contain the WCGHCK motif and are related, in pri-
mary as well as three-dimensional structures, to thioredoxin
[34]. The b and bP domains are also similar to each other
though to a lesser extent, fairly divergent between species,
devoid of CGHC motif, but appear structurally related to
the a and aP domains [35]. The bP domain was proposed to
be involved in peptide and protein binding properties of PDIs
[36]. The c domain (V30 residues) mainly consisting of acidic
amino acid residues in mammalians and yeast (s 50% are D
and E) could be involved in the calcium binding ability of
PDI, but would not be required neither for disul¢de isomerase
nor for chaperone activities of PDI [37]. Noteworthy PDIs
from a number species do not have a very acidic c domain
[17].
A multiple sequence alignment performed with the P. falci-
parum PDI homologue and PDIs from various species (Fig. 3)
allowed to identify the a and aP domains of the P. falciparum
PDI homologue, which were found to display 31^53% amino
acid identities with the a and aP domains of the various PDIs
known, one of the highest similarities (52% identity) being
with the human PDI [38]. The b and bP domains of the P.
falciparum PDI homologue were, as expected, more distantly
related to the various PDIs known, the best amino acid sim-
ilarities being with PDIs from plants (29% identity for Med-
icago sativa [39]), protozoans (28% identity for Cryptosporidi-
um parvum [40]) and fungi (27% identity with Humicola
insolens [41]). The c domain of the P. falciparum PDI homo-
logue was clearly not particularly acidic (only 26% D and E
residues) but this should not, in theory, prevent this enzyme
from displaying either disul¢de isomerase or chaperone activ-
ities.
In summary, the P. falciparum gene we have isolated in this
study encodes a protein displaying all the structural features
and consensus sequences expected for a typical PDI and cor-
responds to Pf52. The experimentally determined and theoret-
ically calculated molecular weight do match, and the six pep-
tide sequences obtained from Pf52 were all found to be
encoded by the gene. Moreover, this P. falciparum PDI ho-
mologue is clearly expressed in erythrocytic stages, since both
the protein and the cDNA from these stages were character-
ized. The fact that PDIs appear essential for cell survival, at
least in another system, and the fact that Pf52 binds to a
potent antiplasmodial inhibitor, strongly suggest that it could
represent a putative target for alternative antimalarial chemo-
therapy.
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